RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $198 from $189 and keeps an Outperform rating on the shares after its Q3 results. The firm continues to see solid commercial execution with good growth potential for Auvelity helped by an improving payer landscape and continued prescriber interest and steady growth for Symbravo and Sunosi, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley
- Axsome Therapeutics price target raised to $178 from $176 at BofA
- Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo
- Axsome Therapeutics Reports Strong Q3 2025 Growth
- Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion